AC
CASI

Aristides Capital’s CASI Pharmaceuticals CASI Stock Holding History

Aristides Capital’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,325
Closed -$152K – 149
2021
Q1 		$152K Buy
+6,325
New +$178K 0.06% 117

Other funds holding CASI

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
IACGFIA
IDG-Accel China Growth Fund III Associates Hong Kong $31.2M AUM 2.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Aristides Capital's CASI Position: Q2 2021 in Review

Aristides Capital sold out of CASI Pharmaceuticals (CASI) in Q2 2021, closing a stake of 6,325 shares — an estimated $152K sold.

Aristides Capital first reported a position in CASI in Q1 2021 and held it in 1 quarter. The position peaked at $152K in Q1 2021. 68 funds tracked by Wall St. Rank hold CASI as of Q2 2021.

  • Aristides Capital reported no remaining CASI Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Aristides Capital sold 6,325 CASI Pharmaceuticals shares in Q2 2021, an estimated $152K.
  • Aristides Capital first reported a position in CASI Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Aristides Capital's CASI Pharmaceuticals position peaked at $152K in Q1 2021.
  • 68 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2021.

Based on Aristides Capital's 13F filing for Q2 2021, filed 16 Aug 2021.